Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FuZhengXiaoJi Decoction is a multi-component traditional Chinese herbal formula investigated for its anti-tumor properties. It has been applied in the clinical treatment of non-small cell lung cancer (NSCLC) and primary liver cancer (PLC). Its mechanism of action involves the modulation of various signaling pathways, including the PI3K/AKT, ERK/MAPK, and JAK1/STAT3/PD-L1 pathways. The decoction influences the expression of key proteins such as AKT1, TP53, and STAT3, and has been shown to attenuate glutathione metabolism. Furthermore, it may play a role in alleviating multidrug resistance in cancer cells by affecting proteins like Multidrug resistance protein 1 and P-glycoprotein. The formula consists of a combination of traditional Chinese medicines, with active compounds potentially including flavonoids, triterpenoids, quercetin, and oleanolic acid.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on FuZhengXiaoJi Decoction.